Julie Ngo
Optometrist · Bellaire, TXNPI 1851541189
Payments from drug & device makers
Across 286 payments — averaging $34.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$1K
- Lumenis BE Inc$1K
- Visioneering Technologies, Inc.$1K
- Sun Pharmaceutical Industries Inc.$790
- Glaukos Corporation$446
- plus $4K from 29 others
What the payments were for
- Food & beverage$9,738100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 28 | $1,237 |
| AbbVie(2 entities) | 62 | $1,133 |
| Lumenis BE Inc | 1 | $1,097 |
| Visioneering Technologies, Inc. | 1 | $1,000 |
| Sun Pharmaceutical Industries Inc. | 39 | $790 |
| Glaukos Corporation | 11 | $446 |
| Oyster Point Pharma, Inc. | 11 | $393 |
| Tarsus Pharmaceuticals, Inc. | 9 | $369 |
| Bausch & Lomb Americas Inc. | 18 | $359 |
| Novartis | 15 | $286 |
| Biotissue Holdings Inc. | 6 | $282 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $269 |
| Eyevance Pharmaceuticals LLC | 9 | $246 |
| Regeneron Healthcare Solutions, Inc. | 10 | $236 |
| Astellas Pharma US Inc | 3 | $182 |
| Harrow Eye, LLC | 7 | $179 |
| Rxsight Inc | 2 | $156 |
| Johnson & Johnson Vision Care, Inc. | 1 | $149 |
| Kala Pharmaceuticals, Inc. | 6 | $145 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $126 |
| Aerie Pharmaceuticals, Inc. | 5 | $99 |
| Genentech USA, Inc. | 3 | $70 |
| Optos, Inc. | 1 | $66 |
| Biogen | 3 | $65 |
| Dompe US, Inc. | 2 | $62 |
| Amgen(2 entities) | 3 | $59 |
| Thea Pharma Inc. | 2 | $48 |
| Ocular Therapeutix, Inc. | 2 | $48 |
| Sight Sciences, Inc. | 2 | $38 |
| Mallinckrodt Enterprises LLC | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Omeros Corporation | 1 | $15 |
| Staar Surgical Company | 1 | $14 |
| Lumenis, Inc | 1 | $14 |
| NEW World Medical,inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$1,097
- Clareon$150
- Acuvue$149
- TOTAL30$139
- RXSIGHT INJECTOR HANDPIECE$132
- RXSIGHT CONTACT LENS$132
- RXSIGHT INJECTOR CARTRIDGE$132
- LIGHT ADJUSTABLE LENS (LAL)$132
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$132
- XDEMVY$126
- TYRVAYA$125
- Izervay$125
- DAILIES$117
- Prokera$116
- AmnioGraft$116
- Zerviate$112
- AcrySof$110
- Photrexa Viscous and Photrexa$101
How this compares
$9,738 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 83 | $108,809 |
| LumiganBimatoprost | 193 | $108,488 |
| XiidraLifitegrast | 43 | $50,327 |
| CombiganBrimonidine Tartrate/Timolol | 61 | $27,847 |
| Cyclosporine | 41 | $27,150 |
| VyzultaLatanoprostene Bunod | 47 | $17,967 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 71 | $12,111 |
| MieboPerfluorohexyloctane/Pf | 13 | $9,793 |
| RhopressaNetarsudil Mesylate | 24 | $8,386 |
| Latanoprost | 415 | $4,496 |
| Brimonidine Tartrate | 103 | $4,140 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $3,603 |
| Prednisolone Acetate | 95 | $3,278 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 206 | $2,981 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,133 | $245,145337 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $359 | $78,087103 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $99 | $11,98935 claims |
| AlconSimbrinza | $1,237 | $2,86511 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $269 | $2,23515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Bellaire
- Jill AutryBellaire$171K
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Derek CunninghamAustin$940K
- Wendy ChungKaty$900K
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Mina VanrachackSan Antonio$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.